ERBA Diagnostics, Inc. Announces Non-Reliance on Previously

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ERBA Diagnostics, Inc. Announces Non-Reliance on Previously Issued Financial Statements

MIAMI LAKES, Fla., Nov. 20, 2015 (GLOBE NEWSWIRE) -- ERBA Diagnostics, Inc. (NYSE MKT:ERB) (the " Company "), a fully integrated in vitro diagnostics company, announced that the Audit Committee of the Company's Board of Directors, after discussion with the Company's management team, concluded that the Company's financial statements for each of the years ended December 31, 2014 and 2013 and for each of the interim periods ended March 31, 2015 and June 30, 2015 (collectively, the " Non-Reliance Periods ") should no longer be relied upon. Further, the Company's disclosures related to such financial statements, such as those included in the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, earnings press releases, earnings conference calls and similar prior communications issued by or on behalf of the Company, with respect to the Non-Reliance Periods should also no longer be relied upon. The Company intends to restate its financial statements for the Non-Reliance Periods by filing amendments to its Annual Report on Form 10-K for the year ended December 31, 2014, which will also include details regarding adjustments in the portion of the Non-Reliance Period occurring during the year ended December 31, 2013, and its Quarterly Reports for the periods ended March 31, 2015 and June 30, 2015 (collectively, the " Restated Filings ") as soon as practicable.

In addition, as the Company had previously reported, the Company has delayed the filing of its Quarterly Report on Form 10-Q for the interim period ended September 30, 2015. The Company expects to file its Quarterly Report on Form 10-Q for the interim period ended September 30, 2015 on or about the same time it files the Restated Filings.

Background

As the Company had previously reported, the Company's management had evaluated the effectiveness of the Company's internal control over financial reporting and, based upon those evaluations, the Company's management had concluded that the Company's internal control over financial reporting was not effective, because there was a material weakness in the Company's internal control over financial reporting as a result of the Company's inadequate staffing of its financial accounting office, which had resulted in, among other things, at times the Company being unable to provide timely account reconciliations. As the Company had also previously reported, the Company's remediation efforts to address this material weakness have been on-going and include, among other things, hiring additional qualified finance personnel and evaluating and undertaking certain improvements to the Company's systems and processes, which, if successful, the Company believes will be sufficient to provide it with the ability to remediate or cure such material weakness in the future. As the Company had also previously reported, in connection with the Company's efforts to improve the effectiveness of its internal control over financial reporting, ERBA Diagnostics has undertaken a review of the intercompany transactions among its subsidiaries and the resulting eliminations made, or required to be made, in the process of producing its consolidated financial statements and their potential impact on reported assets and liabilities.

During the third quarter of 2015, the Company implemented, among other things, a new, enhanced balance sheet review process, with a particular focus on reconciliation of significant accounts, including, among others, intercompany accounts and corresponding eliminations made, or required to be made, at the consolidated level, and their potential impact on its consolidated financial statements. In the course of implementing such new, enhanced review process and reviewing such transactions among its subsidiaries and the resulting eliminations made, or required to be made, in the process of producing its consolidated financial statements as discussed above, the Company identified materially out of balance accounts evident in the elimination process and noted erroneous recording of transactions to such intercompany and other accounts throughout the Non-Reliance Periods. The Company's review of these matters is on-going.

Expected Impact of Restatements

Preliminary indications from the Company's review are that the necessary adjustments to the Company's financial statements during the Non-Reliance Periods are expected to result in an aggregate decrease in net income (or increase in net loss) in the approximate range of $3.0 - $4.0 million, as well as in a shift of certain previously recorded income and expense items to the appropriate periods throughout the Non-Reliance Periods. The Company expects these adjustments to materially impact cost of goods sold, general and administrative expense and various off-setting balance sheet accounts. The Company has not yet completed its final determination and review of the matters discussed above and, therefore, the amounts described above and the periods to which they relate are preliminary, unaudited estimates that are subject to change. There can be no assurance that the final amounts and adjustments will not differ materially from the estimated amounts described above, or that additional adjustments will not be identified, the impact of which may be material.

The Audit Committee has discussed the matters set forth in this press release with the Company's independent registered public accounting firm – Mayer Hoffman McCann P.C.

Cautionary Statement Concerning Forward Looking Statements

The Company has made forward-looking statements, which are subject to risks and uncertainties and which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, in this press release. Forward-looking statements may be preceded by, followed by or otherwise include the words "may," "will," "believes," "expects," "anticipates," "intends," "plans," "estimates," "projects," "could," "would," "should," or similar expressions or statements that certain events or conditions may occur. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by these forward-looking statements. These forward-looking statements are based largely on the Company's expectations and the beliefs and assumptions of the Company's management and on the information currently available to it and are subject to a number of risks and uncertainties, including, but not limited to, the risks and uncertainties that: the Company's review of the matters described above is on-going and the amounts at issue and the periods to which they relate have not been definitively determined; the amounts described above and the periods to which they relate are preliminary, unaudited estimates that are subject to change; the final amounts and adjustments may differ materially from the estimated amounts described above; additional adjustments may be identified, the impact of which may be material; the Company's review of the matters described above may take longer to complete than anticipated; the Company's financial results for the Non-Reliance Periods to be included in the Restated Filings may take longer to prepare than anticipated; the Company's financial results for the interim period ended September 30, 2015 may take longer to prepare than anticipated; the Company may not be able to file its Quarterly Report on Form 10-Q for the interim period ended September 30, 2015 when anticipated; the Company may receive a non-compliance or delisting letter from the NYSE MKT regarding the Company's failure to timely file its Quarterly Report on Form 10-Q for the interim period ended September 30, 2015, regarding the Company's announcement of non-reliance upon its financial statements for the Non-Reliance Periods or regarding the necessity to make the Restated Filings; the NYSE MKT may initiate delisting proceedings, which could result in the Company's common stock being delisted by the NYSE MKT; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. See also the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2014, for further discussion of certain risks and uncertainties that could materially and adversely affect our business, operating results or financial condition. Many of these factors are beyond the Company's control.

About ERBA Diagnostics, Inc.

ERBA Diagnostics, Inc. (NYSE MKT:ERB), is a fully integrated in vitro diagnostics company, offering a comprehensive suite of clinical testing products throughout the U.S. and emerging markets. The Company serves as a one-stop shop for the testing needs of the growing number of smaller hospitals, reference labs, and physician clinics. ERBA Diagnostics' line of proprietary and automated instruments, test kits, and reagents provide customers with autoimmune, infectious diseases, clinical chemistry, hematology, and diabetes testing.  www.erbadiagnostics.com

Mohan Gopalkrishnan 305 418 2320

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 122

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 491

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 307

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 20

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 74

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 207

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 75

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 58

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 160

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza

Updated Category News Views 14

Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...

Continue Reading

Top 5 Most Recently Viewed Articles

Genius Group Takes Center Stage at Major Investor Events

Updated Category News Views 214

Genius Group Highlights Major Sponsorships in 2025 Genius Group Limited (NYSE: GNS), an AI-driven education enterprise that prioritizes Bitcoin, has announced its participation in two pivotal investor summits. These events provide a significant platform for the company to engage with institutional investors and emphasize its innovative approach to digital assets. Engaging...

Continue Reading
Miami International Holdings Celebrates Robust Q3 Growth

Updated Category News Views 172

Miami International Holdings Reports Strong Financial Performance Miami International Holdings, Inc. (MIH) (NYSE: MIAX) has recently announced impressive financial outcomes for its third quarter, highlighting a remarkable growth trend. The financial data unveiled reflects the organization's ability to thrive in a highly competitive landscape. With a net revenue increase...

Continue Reading
Market Insights: Momo Crowd and GM's Tariff Burdens

Updated Category News Views 382

Understanding Momo Crowd Dynamics in Today's Market The stock market consistently reflects a myriad of influences, one of which is the behavior of retail investors, commonly referred to as the 'momo crowd.' Recent analyses indicate that the actions of these investors can significantly shape market trends, especially during times of heightened volatility. The Cautionary...

Continue Reading
Cathie Wood Praises Shopify: The Future of AI in Retail Awaits

Updated Category News Views 129

Cathie Wood's Enthusiastic Endorsement of Shopify ARK Invest, led by the visionary Cathie Wood, has recently expressed considerable confidence in Shopify Inc. SHOP. This faith stems from the company's forward-thinking approach toward artificial intelligence, particularly their dedicated focus on what they call 'agentic AI'. As the retail landscape evolves, many investors...

Continue Reading
Liftoff IPO: What’s the Real Play Behind the Curtain?

Updated Category News Views 244

Liftoff Mobile's been in the game since day one—on February 17, 2026, they dropped a bombshell, submitting their draft registration statement for an initial public offering (IPO) with the SEC. But hold your horses: nobody knows how many shares will float or what price range they’re angling for. That vagueness? Classic Wall Street move to stir up speculation while...

Continue Reading